Australian pre-clinical muscle and metabolic disease biotechnology company Myopharm has announced the appointment of Andrew Plympton AM as its new chair.
Mr Plymton has served as chairman and director on nine ASX-listed entitles, ranging from companies in aerospace, manufacturing, education, labour-hire and Bitcoin.
Mr Plymton has also served on the boards of a number of sporting organisations, including as chair of AFL club St Kilda for seven years, as well a long tenure as an Australian Olympic Committee member.
He is currently the chair of ASX-listed Harris Technology.
Mr Plympton is a business risk expert having served in the operations of two global insurance broking firms, including Anon, as well as McDonald’s restaurants.
“I look forward to using my experience in dealing with both the business and government sector to help guide the company as it shepherds the products of formidable intellectual horsepower toward commercial development,” said Mr Plympton.
“It is satisfying to be involved with, and offer support to, deserving emerging companies such as Myopharm.”
Mr Plympton has replaced interim chair Ashley Arnott, who will remain on the board as a non-executive director.